基因的共同研究及授权契约:2018年～2025年

"基因组合作与授权协议" 提供了前所未有的途径，让我们能够全面了解世界领先生物製药公司达成的基因组协议。

本报告经过全面修订和更新，提供了 2018 年至 2025 年基因组交易的详细资讯。它详细了解并分析了公司达成基因组交易的方式和原因。这些交易通常涉及多个环节，从合作研发开始，到成果商业化结束。

本报告涵盖合作、开发、研究和授权交易。

本报告包​​含自 2018 年以来宣布的 639 项基因组交易的完整列表，包括财务条款（如有），以及交易方披露的实际基因组合作交易的在线交易记录链接。此外，报告还收录了公司及其合作伙伴向美国证券交易委员会提交的合约文件（如有）。

本报告第一章介绍了基因组学交易。

第一章是对报告的介绍。

第二章概述了自2018年以来的基因组学交易趋势。

第三章概述了自2018年以来的主要基因组学交易。交易按交易金额排序。

第四章列出了在基因组学交易中最活跃的25家公司，并附有简要摘要，随后是基因组学交易的完整列表以及公开的合约文件。

第五章对自2018年1月以来签署和宣布的基因组学交易进行了全面深入的回顾，合约文件已公开发布。

第六章全面深入地回顾了自2018年1月以来签署和宣布的基因组学合作交易。本章按感兴趣的特定基因组学技术类型进行组织。

报告还包含大量图表，展示了自2018年以来基因组学交易的趋势和活动。

此外，综合交易目录按公司A-Z、交易类型和治疗目标进行组织。每个交易标题都透过网页连结连结到线上交易记录，并包含合约文件（如有），方便您随时存取每份交易文件。

主要优势

基因体学合作与授权交易提供读者以下主要优势：

• 了解 2018 年及以后的交易趋势
• 浏览基因体学合作与授权交易
• 基准分析 - 确定交易的市场价值
• 财务条款 - 一次性付款、里程碑付款、特许权使用费
• 按公司 A-Z、交易类型和治疗领域分类的交易目录
• 主要交易价值
• 最活跃的交易撮合者
• 确定每笔交易的资产和交易条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款是否适合您的合作公司
• 节省数百小时的研究时间

研究范围

• 基因组学合作与许可交易 "许可协议" 旨在深入了解基因组学趋势以及世界领先生物製药公司达成的交易结构。

基因体学合作与授权协议包括：

• 生物製药产业的基因组学交易趋势
• 涵盖製药和生物技术的基因组学交易记录目录
• 按价值排序的主要基因组学交易
• 最活跃的基因组学许可交易撮合者
• "基因组学合作与许可协议" 提供全面的交易记录存取权限，包括合约文件（如有）。

分析合约文件有助于进行尽职调查：

• 授予或选择的具体权利是什么？
• 合约实际上授予了合作公司哪些权利？
• 授予了哪些独家权利？
• 合约的付款结构是怎样的？
• 如何审计销售和付款？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 如何处理并拥有知识产权？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 如何管理保密和资讯揭露？
• 如何解决争议？
• 合约在什么情况下可以终止？
• 如果所有权发生变更会怎样？
• 双方约定了哪些分授权和分包条款？
• 公司坚持哪些标准条款？
• 哪些标准条款似乎因合作伙伴和交易类型的不同而有所差异？
• 公司在契约法方面主张哪些管辖权？

目录

摘要整理

第1章 简介

第2章 基因交易趋势

• 简介
• 多年的基因交易
• 最活跃的基因交易业者
• 基因交易，各交易类型
• 基因交易，各治疗领域
• 基因交易，各业界
• 基因交易的交易条件
  • 基因交易的主要价值
  • 基因交易的预付款金
  • 基因交易的里程金
  • 基因特许权率

第3章 -主要基因交易

• 简介
• 基因相关交易前几名，各金额

第4章 -最活跃的基因交易业者

• 简介
• 最活跃的基因交易业者
• 最活跃的基因交易企业简介

第5章 基因契约交易名录

• 简介
• 基因契约交易名录

第6章 -各技术类型的基因交易

• 交易名录
• 交易名录- 基因交易(AZ)，各企业
• 交易名录- 基因交易，各交易类型
• 交易名录- 基因交易，各治疗领域
• 交易类型定义
• 关于调查公司
• 目前联盟
• 目前契约
• 最近的报告标题

Genomic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genomic deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of genomic deals from 2018 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter genomic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 639 genomic deals announced since 2018 including financial terms where available including links to online deal records of actual genomic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of genomic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in genomic dealmaking since 2018.

Chapter 3 provides an overview of the leading genomic deals since 2018. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomic dealmaking with a brief summary followed by a comprehensive listing of genomic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of genomic deals signed and announced since Jan 2018, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of genomic partnering deals signed and announced since Jan 2018. The chapter is organized by specific genomic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in genomic deal making since 2018.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Genomic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2018
• Browse genomic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Genomic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of genomic trends and structure of deals entered into by leading biopharma companies worldwide.

Genomic Collaboration and Licensing Deals includes:

• Trends in genomic dealmaking in the biopharma industry
• Directory of genomic deal records covering pharmaceutical and biotechnology
• The leading genomic deals by value
• Most active genomic licensing dealmakers
• Genomic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in genomic dealmaking

• 2.1. Introduction
• 2.2. Genomic deals over the years
• 2.3. Most active genomic dealmakers
• 2.4. Genomic deals by deal type
• 2.5. Genomic deals by therapy area
• 2.6. Genomic deals by industry sector
• 2.7. Deal terms for genomic deals
  • 2.7.1 Genomic deals headline values
  • 2.7.2 Genomic deal upfront payments
  • 2.7.3 Genomic deal milestone payments
  • 2.7.4 Genomic royalty rates

Chapter 3 - Leading genomic deals

• 3.1. Introduction
• 3.2. Top genomic deals by value

Chapter 4 - Most active genomic dealmakers

• 4.1. Introduction
• 4.2. Most active genomic dealmakers
• 4.3. Most active genomic deals company profiles

Chapter 5 - Genomic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Genomic contracts dealmaking directory

Chapter 6 - Genomic dealmaking by technology type

• Deal directory
• Deal directory - Genomic deals by company A-Z
• Deal directory - Genomic deals by deal type
• Deal directory - Genomic deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Genomic deals since 2018
• Figure 2: Active genomic dealmaking activity - 2018 - 2025
• Figure 3: Genomic deals by deal type since 2018
• Figure 4: Genomic deals by therapy area since 2018
• Figure 5: Genomic deals by industry sector since 2018
• Figure 6: Genomic deals with a headline value
• Figure 7: Genomic deals with an upfront value
• Figure 8: Genomic deals with a milestone value
• Figure 9: Genomic deals with a royalty rate value
• Figure 10: Top genomic deals by value since 2018
• Figure 11: Most active genomic dealmakers 2018 - 2025
• Figure 12: Genomic deals by technology type since 2018